DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor

DiaMedica Therapeutics Inc.

Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.
Julie Krop appointed as CMO effective Aug 11, 2025; Krop brings 20+ years experience, most recently CMO at PureTech Health.
Krop previously CMO at Freeline Therapeutics and AMAG Pharmaceuticals; involved in preeclampsia drug development at AMAG.
Krop will lead clinical development of DM199 for preeclampsia and acute ischemic stroke.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.